(Q36255181)

13 August 2017

1 reference

title

The efficacy and safety of PDE5 inhibitors (English)

1 reference

13 August 2017

Aly Rashid

1

1 reference

PubMed ID

16156423

13 August 2017

language of work or name

1 reference

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

7

1 reference

13 August 2017

1

1 reference

13 August 2017

47-56

1 reference

Guidelines on erectile dysfunction

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

1 reference

7 January 2021

Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

The efficacy of sildenafil citrate (Viagra) in clinical populations: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Sildenafil for male erectile dysfunction: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

The efficacy and safety of tadalafil: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Tadalafil in the treatment of erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Safety and Efficacy of Vardenafil for the Treatment of Men With Erectile Dysfunction After Radical Retropubic Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Evaluation of vardenafil and sildenafil on cardiac repolarization

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Commentary on the possibility that Viagra may contribute to transmission of HIV and other sexual diseases among older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Screening for potentially transmitting sexual risk behaviors, urethral sexually transmitted infection, and sildenafil use among males entering care for HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2805%2980048-1

7 January 2021

10.1016/S1098-3597(05)80048-1

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16156423